Brief: PDS Biotechnology Announces Achievement Of Efficacy Threshold In Stage 2 Versatile-002 Trial
14/06/2023 13:27
June 14 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECHNOLOGY ANNOUNCES ACHIEVEMENT OF EFFICACY
THRESHOLD IN
STAGE 2 OF THE VERSATILE-002 TRIAL EVALUATING PDS0101 AND
KEYTRUDA® IN HEAD AND NECK CANCER
* PDS BIOTECHNOLOGY CORP - IN PREPARATION FOR VERSATILE-003
TRIAL,
PLANS TO SUBMIT AN AMENDED IND APPLICATION TO FDA IN Q3 OF 2023
Source text for Eikon: ID:nGNX7BQgF0
Further company coverage: PDSB.O
(reuters.briefs@thomsonreuters.com)
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing